Targeting protein aggregation for the treatment of neurodegenerative diseases  

作　　者：Qingchao Li Wei Pan Jun Zhou Haiyang Yu Songbo Xie 

机构地区：[1]Center for Cell Structure and Function,Shandong Provincial Key Laboratory of Animal Resistance Biology,College of Life Sciences,Shandong Normal University,Jinan 250014,China [2]State Key Laboratory of Medicinal Chemical Biology,Haihe Laboratory of Cell Ecosystem,College of Life Sciences,Nankai University,Tianjin 300071,China [3]Department of Neuroscience,Genentech,South San Francisco,CA 94080,USA [4]Department of Ophthalmology,Tianjin Key Laboratory of Ocular Trauma,Tianjin Medical University General Hospital,Tianjin 300052,China

出　　处：《Medicine Plus》2024年第1期3-7,共5页医学+（英文）

基　　金：supported by the National Natural Science Foundation of China(32270892 and 32070708).

摘　　要：Pathological protein aggregation is a prevalent characteristic of major age-related neurodegenerative diseases,including Alzheimer's disease(AD),Huntington's disease(HD),amyotrophic lateral sclerosis(ALS),frontotemporal dementia(FTD),and Parkinson's disease(PD),and serves as a crucial biomarker for the diagnosis and classification.Although the etiological role of protein aggregation in neurodegenerative diseases is under debate,it is believed to be associated with disease progression and clinical outcomes.1 Therefore,a comprehensive understanding of how protein aggregation forms and clears holds immense potential for discovering and developing therapeutic drugs against neurodegenerative diseases.

关 键 词：aggregation NEUROD protein DEGENERATIVE diseases TARGETING TREATMENT 

分 类 号：R741[医药卫生—神经病学与精神病学]